ProShare Advisors
YMAB

ProShare Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

ProShare Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,109
Closed -$44.8K – 2198
2025
Q1 		$44.8K Sell
10,109
-2,536
-20% -$14.7K ﹤0.01% 1964
2024
Q4 		$99K Buy
+12,645
New +$154K ﹤0.01% 2077
2022
Q2 		– Sell
-11,069
Closed -$132K – 2158
2022
Q1 		$132K Sell
11,069
-2,710
-20% -$27.8K ﹤0.01% 1981
2021
Q4 		$224K Sell
13,779
-8
-0.1% -$171 ﹤0.01% 1961
2021
Q3 		$393K Sell
13,787
-3,107
-18% -$97.9K ﹤0.01% 1359
2021
Q2 		$571K Buy
16,894
+2,724
+19% +$87.4K ﹤0.01% 1438
2021
Q1 		$429K Buy
14,170
+1,158
+9% +$47.5K ﹤0.01% 1539
2020
Q4 		$644K Buy
13,012
+2,894
+29% +$134K ﹤0.01% 1111
2020
Q3 		$388K Sell
10,118
-305
-3% -$12.1K ﹤0.01% 1039
2020
Q2 		$450K Buy
+10,423
New +$394K ﹤0.01% 999
2020
Q1 		– Sell
-11,795
Closed -$369K – 1616
2019
Q4 		$369K Buy
+11,795
New +$349K ﹤0.01% 1231

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ProShare Advisors's YMAB Position: Q2 2025 in Review

ProShare Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 10,109 shares — an estimated $44.8K sold.

ProShare Advisors first reported a position in YMAB in Q4 2019 and held it in 11 quarters. The position peaked at $644K in Q4 2020. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • ProShare Advisors reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,109 Y-mAbs Therapeutics shares in Q2 2025, an estimated $44.8K.
  • ProShare Advisors first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 11 quarters.
  • ProShare Advisors's Y-mAbs Therapeutics position peaked at $644K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.